ANNALS OF NEUROLOGY, cilt.77, sa.3, ss.425-435, 2015 (SCI-Expanded)
ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.